Cargando…

Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction

INTRODUCTION: Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1(TIMP-1) concentration, myo...

Descripción completa

Detalles Bibliográficos
Autores principales: Minicucci, Marcos F., dos Santos, Priscila P., Rafacho, Bruna P. M., Gonçalves, Andrea F., Silva, Renata A. C., Chiuso-Minicucci, Fernanda, Azevedo, Paula S., Polegato, Bertha F., Okoshi, Katashi, Pereira, Elenize J., Paiva, Sergio A. R., Zornoff, Leonardo A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786966/
https://www.ncbi.nlm.nih.gov/pubmed/24098808
http://dx.doi.org/10.1371/journal.pone.0076866
_version_ 1782477808558145536
author Minicucci, Marcos F.
dos Santos, Priscila P.
Rafacho, Bruna P. M.
Gonçalves, Andrea F.
Silva, Renata A. C.
Chiuso-Minicucci, Fernanda
Azevedo, Paula S.
Polegato, Bertha F.
Okoshi, Katashi
Pereira, Elenize J.
Paiva, Sergio A. R.
Zornoff, Leonardo A. M.
author_facet Minicucci, Marcos F.
dos Santos, Priscila P.
Rafacho, Bruna P. M.
Gonçalves, Andrea F.
Silva, Renata A. C.
Chiuso-Minicucci, Fernanda
Azevedo, Paula S.
Polegato, Bertha F.
Okoshi, Katashi
Pereira, Elenize J.
Paiva, Sergio A. R.
Zornoff, Leonardo A. M.
author_sort Minicucci, Marcos F.
collection PubMed
description INTRODUCTION: Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1(TIMP-1) concentration, myocyte hypertrophy, left ventricular architecture, and in vitro and in vivo cardiac function. METHODS: Wistar rats were assigned to 4 groups: control group, in which animals were submitted to simulated surgery (SHAM group; n=9); group that received spironolactone and in which animals were submitted to simulated surgery (SHAM-S group, n=9); myocardial infarction group, in which animals were submitted to coronary artery ligation (MI group, n=15); and myocardial infarction group with spironolactone supplementation (MI-S group, n=15). The rats were observed for 3 months. RESULTS: The MI group had higher values of left cardiac chambers and mass index and lower relative wall thicknesses compared with the SHAM group. In addition, diastolic and systolic functions were worse in the MI groups. However, spironolactone did not influence any of these variables. The MI-S group had a lower myocardial hydroxyproline concentration and myocyte cross-sectional area compared with the MI group. Myocardial periostin and collagen type III were lower in the MI-S group compared with the MI-group. In addition, TIMP-1 concentration in myocardium was higher in the MI-S group compared with the MI group. CONCLUSIONS: The predominant consequence of spironolactone supplementation after MI is related to reductions in collagens, with discrete attenuation of other remodeling variables. Importantly, this effect may be modulated by periostin and TIMP-1 levels.
format Online
Article
Text
id pubmed-3786966
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37869662013-10-04 Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction Minicucci, Marcos F. dos Santos, Priscila P. Rafacho, Bruna P. M. Gonçalves, Andrea F. Silva, Renata A. C. Chiuso-Minicucci, Fernanda Azevedo, Paula S. Polegato, Bertha F. Okoshi, Katashi Pereira, Elenize J. Paiva, Sergio A. R. Zornoff, Leonardo A. M. PLoS One Research Article INTRODUCTION: Our objective was to analyze the effect of spironolactone on cardiac remodeling after experimental myocardial infarction (MI), assessed by matricellular proteins levels, cardiac collagen amount and distribution, myocardial tissue metalloproteinase inhibitor-1(TIMP-1) concentration, myocyte hypertrophy, left ventricular architecture, and in vitro and in vivo cardiac function. METHODS: Wistar rats were assigned to 4 groups: control group, in which animals were submitted to simulated surgery (SHAM group; n=9); group that received spironolactone and in which animals were submitted to simulated surgery (SHAM-S group, n=9); myocardial infarction group, in which animals were submitted to coronary artery ligation (MI group, n=15); and myocardial infarction group with spironolactone supplementation (MI-S group, n=15). The rats were observed for 3 months. RESULTS: The MI group had higher values of left cardiac chambers and mass index and lower relative wall thicknesses compared with the SHAM group. In addition, diastolic and systolic functions were worse in the MI groups. However, spironolactone did not influence any of these variables. The MI-S group had a lower myocardial hydroxyproline concentration and myocyte cross-sectional area compared with the MI group. Myocardial periostin and collagen type III were lower in the MI-S group compared with the MI-group. In addition, TIMP-1 concentration in myocardium was higher in the MI-S group compared with the MI group. CONCLUSIONS: The predominant consequence of spironolactone supplementation after MI is related to reductions in collagens, with discrete attenuation of other remodeling variables. Importantly, this effect may be modulated by periostin and TIMP-1 levels. Public Library of Science 2013-09-30 /pmc/articles/PMC3786966/ /pubmed/24098808 http://dx.doi.org/10.1371/journal.pone.0076866 Text en © 2013 Minicucci et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Minicucci, Marcos F.
dos Santos, Priscila P.
Rafacho, Bruna P. M.
Gonçalves, Andrea F.
Silva, Renata A. C.
Chiuso-Minicucci, Fernanda
Azevedo, Paula S.
Polegato, Bertha F.
Okoshi, Katashi
Pereira, Elenize J.
Paiva, Sergio A. R.
Zornoff, Leonardo A. M.
Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
title Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
title_full Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
title_fullStr Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
title_full_unstemmed Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
title_short Mechanisms Involved in the Beneficial Effects of Spironolactone after Myocardial Infarction
title_sort mechanisms involved in the beneficial effects of spironolactone after myocardial infarction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786966/
https://www.ncbi.nlm.nih.gov/pubmed/24098808
http://dx.doi.org/10.1371/journal.pone.0076866
work_keys_str_mv AT minicuccimarcosf mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT dossantospriscilap mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT rafachobrunapm mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT goncalvesandreaf mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT silvarenataac mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT chiusominicuccifernanda mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT azevedopaulas mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT polegatoberthaf mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT okoshikatashi mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT pereiraelenizej mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT paivasergioar mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction
AT zornoffleonardoam mechanismsinvolvedinthebeneficialeffectsofspironolactoneaftermyocardialinfarction